Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 3/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751947 | 1.00 | DPP7 (0.50) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL10520841 | 0.92 | DPP7 (0.62) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL8495681 | 0.91 | DPP7 (0.56) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL1888867 | 0.89 | FOLH1 (0.47) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL8567236 | 0.89 | FOLH1 (0.47) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL1889778 | 0.89 | DPP8 (0.47) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL6255972 | 0.89 | DPP8 (0.47) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL6255984 | 0.89 | DPP8 (0.47) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL2192330 | 0.89 | DPP8 (0.45) | DPP7DPP8DPP9GSRGNAI3 | |
| SCHEMBL2192260 | 0.89 | DPP8 (0.47) | DPP7DPP8DPP9GSRGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175872-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION | 2022-06-09 | — | — | US | claimed |
| US-10098967-B2 | Self-assembly of therapeutic agent-peptide nanostructures | OHIO STATE INNOVATION FOUNDATION (US) | 2018-10-16 | — | — | US | claimed |
| US-20180185502-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION | 2018-07-05 | — | — | US | claimed |
| WO-2017172881-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-05 | — | — | WO | claimed |
| WO-2016210141-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2016-12-29 | — | — | WO | claimed |
| US-20140155577-A1 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2014-06-05 | — | — | US | claimed |
| US-4861755-A | Peptides with vasorelaxant, natriuretic and diuretic effects a process for their preparation, agents containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-29 | — | — | US | claimed |
| CN-111902394-B | Compositions and methods relating to salts of specific pro-inflammatory regressive mediators | 西蒂斯制药有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20220175872-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION | 2022-06-09 | — | — | US | disclosed |
| US-20190083574-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION (US) | 2019-03-21 | — | — | US | disclosed |
| US-10098967-B2 | Self-assembly of therapeutic agent-peptide nanostructures | OHIO STATE INNOVATION FOUNDATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180185502-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION | 2018-07-05 | — | — | US | disclosed |
| WO-2017172881-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2016210141-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20140155577-A1 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2014-06-05 | — | — | US | disclosed |
| EP-1068313-A2 | COLLAGEN PEPTIDES AND USES THEREOF | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050281-A2 | COLLAGEN PEPTIDES AND USES THEREOF | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 1999-10-07 | — | — | WO | disclosed |
| US-4861755-A | Peptides with vasorelaxant, natriuretic and diuretic effects a process for their preparation, agents containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185502-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | CA1, CPN1, CA7 | DPP7 493/4885DPP8 275/4885DPP9 1839/4885 |
| US-20220175872-A1 | THERMOGENIC COMPOSITIONS AND METHODS | LRBA, IAPP, FABP4 | DPP7 57/4885DPP8 147/4885DPP9 95/4885 |
| US-20140155577-A1 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES | IAPP, TAP1, LNPEP | DPP7 365/4885DPP8 449/4885DPP9 626/4885 |
| US-10098967-B2 | Self-assembly of therapeutic agent-peptide nanostructures | IAPP, NPPA, TAP1 | DPP7 162/4885DPP8 259/4885DPP9 525/4885 |
| US-20190083574-A1 | THERMOGENIC COMPOSITIONS AND METHODS | LRBA, IAPP, FABP4 | DPP7 57/4885DPP8 147/4885DPP9 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.